General AML

Jeffrey E. Lancet | ISAL 2019 | The role of CPX 351 in AML

L:

ACUTE LEUKEMIAS XVII Biology and Treatment Strategies, February 24-27 2019, Munich, DE

Jeffrey E. Lancet

Moffitt Cancer Center & Research Institute, Tampa, US

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!